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ABSTRACT

Inflammation is known as a mechanism to regulate and control infections as well as promote tissue
repair. Macrophages (Mф) are known to be a major cell type in the initiation, sustainability and
resolution of inflammation. Moreover, Mф are essential for the remodeling process that is also
known as the wound healing response. The objective of this research was to compare five
modulators (acetylsalicylic acid (ASA), dexamethasone (DEX), prostaglandin E2 (PGE2), iloprost,
and resolvin D1 (RvD1) for their anti-inflammatory effects on macrophages in vitro. Then, Mф
phenotype in terms of gene expression and secreted cytokine response was determined. Our study
compared NR8383 cells induced with LPS versus a modulator. Using ELISA measurements of
chemokine (C-C motif) ligand 2 (CCL2), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor
necrosis factor alpha (TNF-α) performed. Gene expression analysis for the following transcripts:
arginase -2 (ARG-2), nitric oxide synthesis type II (iNOS-2), macrophage - associated antigen
(CD163) is known to be expressed by M2c phenotype and mannose receptor C type 1 (CD206) is
known to be expressed by the cells of the M2 phenotype. In conclusion, each modulator has shown
to present an anti-inflammatory response and acetylsalicylic acid (ASA), dexamethasone (DEX)
and prostaglandin E2 (PGE2) did express CD163. Future work, further analysis will be necessary
any functional of these in in vivo.
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SIGNIFICANCE

Macrophages are one of the major cells that affect inflammation. One role of macrophages is to
promote phagocytosis, but also macrophages are essential for the remodeling process which
requires the balancing of inflammation. The objective of this research was to induce macrophage
to a more anti-inflammatory state with different well-known modulators to compare protein
secretion and macrophage activation. With these in vitro comparisons, it is possible to obtain a
better understanding of the cytokine secretion and macrophage activation induced by each
modulator, and also obtains better understanding of these modulators as a counterbalance to proinflammatory responses. Acetylsalicylic acid (ASA), dexamethasone (DEX), prostaglandin E2
(PGE2), prostaglandin I2 and resolvin D1 (RvD1) are modulators which are known to produce an
anti-inflammatory response (El et al., 2002; Kopp and Ghosh, 1994; MacKenzie et al., 2013; Titos
et al., 2011; Zhou et al., 2007). The anti-inflammatory properties of each of these modulators can
be used to alter macrophage phenotype. By altering the macrophage phenotype, it may be possible
to improve biomaterial longevity and decrease formation of scar tissue.

INTRODUCTION

Inflammation is a complex mechanism of the innate immune system that involves recruitment of
leukocytes and plasma proteins into sites of infection or tissue injury. Moreover, inflammation can
also be triggered by molecular signals that are common features of microbes or dead cells. These
patterns are known as pattern recognition receptors; for example, toll-like receptors (TLRs) which
recognize bacterial DNA, virus, and other pathogens. In addition, inflammation is regulated by the
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body to control infections and promote tissue repair, but also can cause tissue damage and disease.
To maintain and promote the recruitment of leukocytes, the cells must be able to be recruited and
transported to the site of which can be explained in two steps (Abbas, 2012):

1. Recruitment and accumulation of leukocytes through the endothelium to the local site of
the injury: this process of recruitment is receptor mediated. For example, TNF-α and LPS
promotes the expression of P-selectin in murine of the endothelial cell surface, and also,
cytokines are regulated from the site of the injury which promote the induction of the
expression of the E-selectin on endothelial cells. The secretion of cytokines is one of the
first responses of the body to an infection, tissue damage or cell death (apoptosis).

2. Migration across into the endothelium: chemokine gradients, which are presented in the
surrounding tissue, display on the endothelial surface. Chemokines, which are produced
around the area, are going to be displaced on the endothelium surface and then bind to the
receptors of the rolling leukocytes. Then, the leukocytes crawl between the endothelium
cells and migrate through the venular. Monocytes, neutrophils and T lymphocytes use this
mechanism to emigrate out of the blood stream (Abbas, 2012).
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One type of cell that rises up into the endothelium by the inflammation mechanism is the
monocyte/macrophage. Monocytes can be described as white blood cells which are being produced
from the bone marrow by the precursor monoblasts, and are being stored in the spleen. Monocytes
are cells that can circulate through the bloodstream, and also can reach into the tissue. Also,
monocytes move through the bloodstream and into the tissue where they differentiate into
macrophages. Macrophages (Mф) are primary cells that can be differentiated from monocytes in
tissue. Mф are known to be a major player in the initiation and resolution of inflammation. Also,
the role of the Mф cell is to phagocytose cells by attacking foreign substances, and also stimulate
lymphocytes and others immune cells to defeat pathogens (Abbas, 2012). Macrophages can be
activated by microbial molecules. For instance, an endotoxin, such as lipopolysaccharide (LPS)
can activate macrophages to secrete numerous pro-inflammatory cytokines such as IL-6, IL-12,
and TNF-α. Moreover, Mф can also switch from a pro-inflammatory to an anti-inflammatory
microenvironment by secreting anti-inflammatory cytokines such as IL-10. Mф can auto-regulate
because macrophages are a type of cell which can switch the phenotype (activation) depending on
the chemicals residing in the microenvironment (Martinez et al., 2008).

In addition, macrophages are essential for the remodeling process that is also known as the wound
healing response. In others studies, the Mф has shown a shifting of polarization which regulates
the remodeling and inflammatory response. These wide-spectra of the macrophage polarity are
handled by the body as either a mechanism of defense which can be expressed as a wound healing
or an immune response. Moreover, Mф cells are known to play a central role in the regulation of
immune responses and also in the acute and chronic inflammation (Garg et al., 2013). Depending
of the microenvironment that Mф are exposed to, these plastic cells can differentiate into M1s
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(which is the classical activation) and M2s (which is the alternative activation). The M1 phenotype
(classical activation) is known to secrete pro-inflammatory cytokines, and also M1s can be
activated by inducing with LPS. To clarify, M1s are induced by interferon-gamma (INF-γ) or
tumor necrosis factor alpha (TNF-α), and secrete pro-inflammatory cytokines such as TNF-α, IL1, IL-6, IL-12 and IL-23 (Mantovani et al., 2013). On the other hand, M2 phenotype (alternative
activation) is known to promote tissue remodeling. Moreover, M2 phenotype activation can be
further classified by subtype M2a, M2b and M2c. M2a phenotype tends to initiate type II
inflammation. This macrophage type is presented against parasites and can be induced by IL-4,
IL-10 and IL-13. M2b phenotype is considered as an immune-regulate/immune-suppressed and
can be induced by IL-10 and TGF-β. Lastly, M2c phenotype is known to participate in matrix
remodeling and tissue repair and can be induced by IL-10 (Martinez et al., 2008). In addition, M1
phenotype should be expressed first and then a transition to the M2 phenotype (Murray et al., 2014)
promote wound remodeling (Garg et al., 2013). Thus, macrophages are known to behave according
to the chemical in the microenvironment; for these reasons Mф can shift polarization depending
on the presence of stimulating molecules.

On the other hand, new guidelines are being proposed to classify macrophages by their activation.
To illustrate, when the cells are induced with LPS, the new guidelines denotation is M (LPS) which
represent as macrophages (M) and LPS as the inducer compound. Another example, when Mф
cells are induced with dexamethasone, the new guidelines denote as an M (DEX).

NF-kB (nuclear factor kappa light chain enhancer of activated B cells), which is a protein complex
that controls DNA transcription, can be triggered by the stimulation of a bacterial infection,
cytokines irradiation and free radical (Shackelford et al., 1997). NF-kB is a rel family transcription
4

factor which is present in the cytosol as a heterodimer of 50 kDa (p50) and 65 kDa (p65, Rel-A),
and it is also bound to an inhibitor to protein subunit IkB (Shackelford et al., 1997). The NF-kB is
known to be stimulated by lipopolysaccharides (LPS), an endotoxin, and TNF-α (tumor necrosis
factor), IL-6 (interleukin) and other pro-inflammatory cytokines in response to induction by LPS.
To clarify, LPS stimulation triggers the release of NF-kB from IkB which results in the
translocation of NF-kB from the cytoplasm to the nucleus whereas NF-kB binds to the DNA of
the cell and regulate the transcription of different genes. As a result of activation, the cells release
pro- inflammatory signaling molecules such as IL-1, IL-6, IL-8, IFN-β, and TNF-α and others
cytokine molecules (Kopp and Ghosh, 1994). On the other hand, modulators can be used to inhibit
the NF-κB protein complex. For example, dexamethasone is known to inhibit NF-κB which results
in lowered production of TNF-α, IL-12 and other pro-inflammatory cytokines. However, several
modulators can be used to inhibit the activation of this protein complex.

Aspirin known as acetylsalicylic acid is the most widely used drug. It is often used as an analgesic
to relive pain, antipyretic to reduce fever, and as an anti-inflammatory drug. Aspirin is the first
known nonsteroidal anti-inflammatory drug (NSAIDs) of which there are now a host of similar
drugs; on the other hand, aspirin differs from other NSAIDs in its mechanism. A treatment at 3
mM of ASA has showed to be a potent anti-inflammatory drug in alveolar macrophages (Duan et
al., 2014). For this reason, concentrations of ASA that was used in our study were in the range
between 0.1 to 10 mM of ASA. In others studies, aspirin has been reported to inhibit NF-kB
through the stabilization of IkB molecule. In cells such as macrophages, NF-kB is known to encode
inflammatory mediator such as TNF-α (Shackelford et al., 1997).
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Figure 1: Molecular structure of acetylsalicylic acid (ASA)

Dexamethasone (DEX) is a known to be a potent glucocorticoid, which is a steroid drug with antiinflammatory properties and immunosuppressant effects. Glucocorticoids are known to inhibit the
expression of inflammation mediators in cells such as macrophages. The anti-inflammatory
response of glucocorticoid have shown to be an effective inhibitor of NF-kB and activator protein
1 (AP-1), which are known to induce an inflammatory effect (Abraham et al., 2006). The activation
of NF-kB and activator protein 1 (AP-1) is induced by LPS which releases TNF-α into the
microenvironment. To illustrate, dexamethasone is known to reduce the pro-inflammatory
molecules by abolishing the pro-inflammatory cytokines: TNF-α, IL-8 and IL-6, but also
exaggerating the anti-inflammatory cytokine: IL-10 (El Azab et al., 2002). In addition, the
concentration of DEX and LPS were obtained from a previous study (Bajpai, 2015).
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Figure 2: Molecular structure of dexamethasone (DEX)

Eicosanoids are lipid-signaling molecules which are known to be present mainly in inflammation
and also these molecules are known to be a messenger in the central nervous systems (Balazy,
2004). Eicosanoids are derived from either omega-3 (ω-3) or omega-6 (ω-6) fatty acids.
Prostaglandins (PGs) are a group from the ω-6 fatty acid family. Prostaglandins are known
compounds which consist of 20 carbons with a 5 carbon ring (Funk, 2001). Moreover, PGs are
known to be secreted in different places in the body, and also PGs can be secreted by mast cell or
basophil and Mф (Abbas, 2012). The prostaglandins are in a subclass of a group called eicosanoids.
The biosynthesis of the prostaglandin starts with the stimulation of toll-like receptor 4 (TLR4) by
induction of LPS which leads to the activation of mitogen-activation protein kinase (MAP kinase)
and IKK pathways. Then, the membrane phospholipid is hydrolyzed, and catalyzed by the enzyme
phospholipid A2 (PLA2)(Sakata et al., 2010). As a result, macrophages or mast cells synthesize
arachidonic acid (AA) which can hydrolyze to obtain prostaglandin G2 (PGG2), and subsequently
prostaglandin H2 (PGH2) by the synthesis of prostaglandin H, which is also known as
cyclooxygenase (COX). COX can be further derived into COX-1 (PTGS-1) and COX-2 (PTGS2). Prostaglandin H2 is an unstable lipid mediator which is soon converted into prostaglandin D2
(PGD2), E2 (PGE2), F (PGF2α), I2 (PGI2), and thromboxane (TXA2) (Fukata and Abreu, 2008).
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In other studies, the receptors that recognize the presence of PGE2, can be further divided into four
types EP1, EP2, EP3, and EP4. The PGE2-EP4 is known to be essential to the transcription factor.
The effect of PGE2 can direct the process of the suppression of inflammation and the enhancement
wound healing (Takayama et al., 2002). Moreover, PGE2 has been shown to inhibit chronic and
acute inflammation in vivo and also can inhibit pro-inflammatory cytokine response in cells such
as macrophages (Vassiliou et al., 2003). In addition, PGE2 (at ~ 10-9 M) can inhibit TNF-α, and IL6 and increase IL-10 in peritoneal macrophages (PM) which were stimulated with LPS 0.5 µg/ mL
for 24 hours (Strassmann et al., 1994). Moreover, LPS and TNF-α can be used to induce the
production of PGE2, on the other hand, the induction of PGE2 with LPS is known to stimulate cells
to inhibit TNF-α mRNA expression and protein secretion (Strassmann et al., 1994).

Figure 3: Molecular structure of prostaglandin E2 (PGE2)

Prostaglandin I2 (PGI2) is a lipid mediator member of the prostaglandin family known as an
eicosanoid. PGI2 is known as a prostacyclin which is a metabolite from arachidonic acid (AA), and
also recent studies have shown it to have anti-inflammatory properties (Zhou et al., 2007).
Prostacyclin receptor (IP1) is a member of the G-protein coupled receptor family. The function of
8

PGI2 exerts through G-proteins couple IP1 and signaling which leads to the raising levels of
intracellular cAMP. However, PGI2 is an unstable molecule in aqueous solution (Cho and Allen,
1978); for this reason, an analog of PGI2 is used iloprost or cicaprost. Iloprost and cicaprost have
shown to inhibit the production of pro-inflammatory signaling molecules such as TNF-α (Eisenhut
et al., 1993). However, iloprost and cicaprost show an increase IL-10 in human peripheral
mononuclear cells in vitro as well (Zhou et al., 2007). Moreover, iloprost and cicaprost also have
shown to inhibit the production of GM-CSF, IL-1, IL-6, and TNF-α and blocked NF-kB nuclear
translocation in human alveolar macrophages (Zhou et al., 2007). Thus, PGE2 and PGI2 are known
to reduce pro-inflammatory response such as TNF-α and IL-6. However, PGI2 analogs (iloprost)
can block the activity of NF-kB.

Figure 4: Molecular structure of iloprost
Resolvin is a potent lipid mediator which derived from docosahexaenoic (DHA) which is group
from the ω-3 fatty acid family. In the inflammatory mechanism, phospholipase enzyme (cPLA2)
is known to release free polyunsaturated fatty acid (PUFA) including arachidonic acid (AA),
docosahexaenoic acid (DHA), and omega-3 fatty acid eicosapentaenoic acid (EPA) which are
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known to initiate a wide-variety of biosynthetic pathways which are known to be hydroxylased by
two different enzymes: lipoxygenase (LOXs) and cyclooxygenase (COX-2). Recent studies have
shown that the activation of the receptor by these lipid signaling mediators can affect levels of the
expression of enzymes levels, chemokines, cytokines, and growth factors which play a
predominate role in the inflammatory response and in the resolution of inflammation (Serhan and
Petasis, 2011).

Resolvin D1 (RvD1) was recently shown to inhibit neutrophil activation, and regulate cytokine
secretion. Recent studies, RvD1 have shown to be a potent anti-inflammatory lipid mediator in
different disease models such as colitis, periodontitis, acute kidney injury and peritonitis (Feng et
al., 2012; Serhan et al., 2008; Serhan and Petasis, 2011). Moreover, RvD1 has been shown to
improve insulin sensitivity in obese diabetic mice (Hellmann et al., 2011). The protective effect is
partially mediated by the suppression of tumor necrosis factor (TNF-α) and also can mediate the
reduction of inflammatory activity of leukocytes. In addition, RvD1 decreases the expression of
the PGE2 levels in macaca mulatta CREC cells line when the molecule is induced by IL-1β (Tian
et al., 2009). Moreover, RvD1 and their precursor DHA have shown to promote the macrophage
polarization to the M2 phenotype (Titos et al., 2011). According to Tito, RvD1 have shown to
promote similar result as IL-4 in the expression of TNF-α and IL-6.(Tian et al., 2009)
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Figure 5: Molecular structure of resolvin D1 (RvD1)

Thus, the concentrations of PGE2, iloprost and RvD1 that was used in our experiment were chosen
using previous studies (Panzer and Uguccioni, 2004; Sun et al., 2007; Yao et al., 2009; Zhou et
al., 2007).

In this present study the aim was to compare five modulators (acetylsalicylic acid (ASA),
dexamethasone (DEX), prostaglandin E2 (PGE2), iloprost and resolvin D1 (RvD1)) for their antiinflammatory effects on macrophages in vitro, and also to understand how they affected the
macrophage phenotypes in terms of gene expression and secreted cytokines. Four well-known
anti-inflammatory and pro-inflammatory cytokines were analyzed:

 Pro-Inflammatory signaling molecules:


Monocyte chemo-attractant protein-1 (MCP-1/CCL2) is a chemokine that is known to
regulate migration and infiltration of monocytes.



Interleukin-6 (IL-6) is known as an anti and pro-inflammatory cytokine responses. The
principal cells sources of IL-6 are macrophages, endothelial cells and T-cells.
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Tumor necrosis factor alpha (TNF-α) is known to be involved in the systemic
inflammation, and also TNF-α is known to stimulate acute inflammatory response. This
cytokine is; also, known to increase collagen, and TNF-α can be secreted by T-cells,
macrophages and other types of cells.

 Anti-Inflammatory signaling molecules:


Interleukin-10 (IL-10) is known anti-inflammatory cytokine. In addition, IL-10 is a known
cytokine which is known to drive macrophage to the M2 phenotype.

In addition to the protein secretion, macrophage polarization was analyzed by the gene expression.
GADPH is known to play a role in glycolysis and nuclear function inside of the cell. Others genes
that were used for the experiment are listed and described as follows:



Arginase -2 (ARG-2) is known to be a protein coding gene. Moreover, ARG-2 plays of
catalyze hydrolysis of arginine to ornithine, and also in the down regulation of nitric oxide
synthesis.



Nitric oxide synthesis type II (iNOS-2) is the enzyme a radical which is known to be a
biologic mediator as a neurotransmission and antimicrobial and antitumor activities. iNOS
is expressed by the combination of lipopolysaccharide (LPS). iNOS is known to mediate
tumoricidal and bactericidal actions.



Macrophage - associated antigen (CD163) may play an anti-inflammatory role and may be
used as a parameter for monitoring macrophage activation in inflammatory conditions.
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Moreover, CD163 expression showed to suppress pro-inflammatory mediators like LPS
and TNF-α and up-regulate mRNA in IL-6 and IL-10 in monocytes and macrophages
(Buechler et al., 2000). CD163 is known to be expressed by cells of the M2c phenotype.



Mannose receptor, C type 1 (CD206) is a protein coding gene, mediates the endocytosis of
glycoprotein and acts as a phagocytosis receptor for bacteria and other pathogens. The
protein is known to attach to high mannose structures on the surface of potential pathogens
such as bacteria, fungi, and virus, and then neutralize by phagocytosis. Moreover, CD206
antigen is known to be expressed by the cells of the M2 phenotype.
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METHODS

Materials
Experiments were conducted using NR8383 cells that were purchased from American Type
Culture Collection (ATCC) (Manassas, VA). Fetal bovine serum was obtained from SigmaAldrich (St. Louis, MO). F-12k media which contained 100 g/mL streptomycin, 0.25 g/mL
amphotericin were obtained from American Type Culture Collection (ATCC) (Manassas, VA) and
2 mM glutamine and antibiotic (penicillin) were obtained from Sigma (St. Louis, MO). The
lipopolysaccharide

Salmunella

typhimurium

(LPS)

was

obtained

from

Calbiochem

(Massachusetts, MA). For the RT-PCR, the Trizol reagent was from Life Technologies (Grand
Island, NY), RNeasy Kit from Qiagen (Germantown, MD) as a column clean up, high capacity
RNA-to-cDNA kit from Life Technologies (Grand Island, NY) and finally primers such as
GADPH

(NM_017008.3)

(NM_001107887.1),

ARG-2

CD-206

(NM_019168.1),

(NM_001106123.1),

iNOS
TNF-α

(NM_012611.3),
(NM_012675.3),

CD-163
CCL2

(NM_031530.1) and IL-10 (NM_012854.2) from Life Technologies (Grand Island, NY). ELISA
kits (CCL2, IL-6, IL-10, and TNF-α) were purchased from BD Biosciences (San Diego, CA).

Cell culture
NR8383 cells were cultured using 15 (v/v %) fetal bovine serum, 1 (v/v %) of 100U/mL penicillin,
and 84 (v/v %) of F-12K which contained a 100 g/mL streptomycin, 0.25 g/mL amphotericin and
2 mM glutamine. Then, the cells were incubated at 37 °C and 5 % CO2.
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Treatment of cell culture for ELISA
Secreted CCL2, IL-6, IL-10, and TNF-α were measured using the procedure specified by the
manufacturer. First, the cells were spun down by centrifugation for 7 min at 1000 rev/min, and
washing using pH of 7.4 of 1x PBS which contained 1.7 M sodium chloride (NaCl), 33 mM
potassium chloride (KCl), 67 mM disodium phosphate (Na2HPO4) and 7.07 mM monopotassium
phosphate (KH2PO4) in 1 L. The cells were resuspended in 1 mL of media, cultured in a 24 well
plates using 1.8 x 105 cells/ mL per well. For the cell count, we used the hemocytometer method
which allows counting cells using 20 µL of trypan blue and 20 µL of cell suspension using a
Countess automated cells counter.

The stock solution for acetylsalicylic acid was prepared by dissolving ASA in 1 mL of warm 50
°C ethanol 99% and then complete it with 1x PBS. The stock solution was prepared at 1 M of
(ethanol and 1x PBS at pH 7.4). In this experiment were three different treatments:

I.

Treatment A was treated with the modulator first and 80 minutes later induced with
endotoxin lipopolysaccharide (LPS) from Salmonella typhimurium.

II.

Treatment B was induced with the endotoxin LPS and 80 minutes later treated with the
modulator later.

III.

Treatment C was induced with the endotoxin LPS and at the same time treated with the
modulator.
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Table 1: Induces and treats for acetylsalicylic acid and dexamethasone
Treatments

First Induction

Second Induction

Modulator (ASA or DEX),
A

LPS
and 80 min later second
induction

B

LPS, and 80 min later second
Modulator (ASA or DEX)
induction

C

Modulator (ASA or DEX),

LPS

and the second induction

Each modulator was induced using different concentration. Table 2 shows each modulator with
the different concentrations. Finally, the plates were incubated for 24 hours.
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Table 2: Modulators
Modulators

Concentration

Hypothesis Effects

Lipopolysaccharide (LPS)

50 ng/mL

Induce inflammation

Acetylsalicylic acid (ASA)

0.1, 1 and 10 mM

Anti-inflammatory modulator

Dexamethasone (DEX)

100 nM

Anti-inflammatory modulator

Prostaglandin E2 (PGE2)

10 nM, 100 nM, and 1 µM

Anti-inflammatory modulator

Iloprost

10 nM, 100 nM, and 1 µM

Anti-inflammatory modulator

Resolvin D1 (RvD1)

10 nM, 100 nM, and1 µM

Anti-inflammatory modulator

ELISA (Enzyme Linked Immunosorbent Assay)
1.8 x 105 cells/ mL of NR8383 cell were harvested. Then, the levels of CCL2, IL-6, IL-10, and
TNF-α in the supernatant only were quantified using ELISA kit following the manufacture`s
procedure.

Treatment of cell culture for the qRT-PCR measurement
Cells were spun down by centrifuge them for 7 min at 1000 rev/min, and washed using 1x of PBS.
After centrifuged the cells and reconstituted using 1 mL of media, the plate were cultured in a 6
well plates using 2.8 x 106 / mL of cells per well. For the PCR analysis were used the same
treatment that was presented in table 1, and the concentration followed for treatment PGE2,
dexamethasone, RvD1 and iloprost. Real time qRT-PCR is a technique that is commonly used for
the quantification of DNA sequences.
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qRT-PCR (Real Time Polymerase Chain Reaction)
After treatment of the cells, the RNA was extracted from the cells (2.8 x 106 cells/ mL) that were
already treated using the Trizol reagent following the manufacture procedure. Then, the total RNA
was quantified using a NanoDrop Spectrophotometer 2000c at 260/280 and 260/230 nm absorption
ratio. Using an agarose electrophoresis gel, the quality of the RNA was checked before synthesized
cDNA by reverse transcription (RT) using a high capacity RNA-to-cDNA kit. Then, the samples
were run in a thermo-cycle PCR TC-3000. Subsequently, the relative levels of target molecules
which were GADPH as a housekeeping gene, and targeted DNA GADPH (NM_017008.3) ARG2

(NM_019168.1),

iNOS

(NM_012611.3),

CD-163

(NM_001107887.1),

CD-206

(NM_001106123.1), TNF-α (NM_012675.3), CCL2 (NM_031530.1) and IL-10 (NM_012854.2)
were determined using qRT-PCR (7500 Real Time PCR System from Applied Bio systems). The
following thermal cycle condition for the qRT-PCR were initial denaturation at 50°C, 40 cycles of
amplification at 95 °C, and then steady at 95°C and finally 60 °C.

Quality of Iloprost
LC/MS analysis was performing on LCMS-8040 triple quadrupole Mass Spectrometer (MS) with
an ESI ion source connected to a Shimadzu Nexera X2 UPLC. The column, for the experiment,
was a Phenomenex Kinetix C18 column (100x 3.0 mm, 2.6 µm particle sizes). Moreover, as a
solvent was used water and methanol and each one contained 0.1% of formic acid. To measure the
sensitivity of the equipment was run an isocratic run with 65% methanol, 0.6 mL/min as a flow
rate and 40°C as a column temperature. Using a selected ion monitoring (SIM) in the MS, 325.3
[M+ H- 2H2O] +, 343.3 [M+ H- H2O] +, 378.3 [M+ NH4] + and 383.3 [M+ Na] + m/z was followed.
These ions are present in iloprost, respectively. Sample of 1 µL of iloprost were injected over a 10
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min run. Then, it was injected a higher concentration of iloprost 10 pg/µL and then a low
concentration of 1 pg/µL.

For the purity of iloprost, the chromatographic condition were 10% v/v (H2O/MeOH), then an
increase to 90% v/v (H2O/MeOH) over 13 min, and then was held at 90% v/v (H2O/MeOH) for 2
min. The flow rate for this experiment was used 0.6 mL/min with a temperature column of 40°C.
MS was scanned from 140 to 800 m/z with a concentration of iloprost of 13.87 mM.

Statistical analysis
Data are expressed as mean ± SE. Statistical significance was estimated using origin software
OriginLab Corporation (Northampton, MA). The method of analyses data for the ELISA was
ANOVA followed by Tukey post-hoc test, and the differences were significant if [p<0.05]. In
addition, for the qRT-PCR were used the relative expression software tool (Multiple condition
solver) REST-MCS version 2 using pair wise fixed reallocation randomization test, and the
differences were significant if (p<0.05).
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RESULTS

1.1 Secretion of anti and pro-inflammatory cytokines treated with acetylsalicylic acid (ASA) in
NR8383 cells.

To examine the concentration of proteins secretion of pro and anti-inflammatory cytokines
responses, (50 ng/mL) LPS was used to induce an inflammatory response in the NR8383 cell line.
Then, from the supernatants ELISA was used to quantify the protein secretion levels of a variety
of cytokines including:


Monocyte chemo-attractant protein-1 (MCP-1/CCL2)



Interleukin-10 (IL-10) an anti-inflammatory cytokine.



Interleukin-6 (IL-6) an anti and pro-inflammatory cytokine.



Tumor necrosis factor alpha (TNF-α) is known to be involved in the systemic
inflammation, and also it is known to stimulate acute inflammatory response.

Figure 6 shows the concentration of protein secreted for CCL2, IL-6, IL-10 and TNF-α. IL-10 did
show significance differences at 0.1 mM of acetylsalicylic acid (treatment C), 1 mM of
acetylsalicylic acid (treatment A and C), and 10 mM of acetylsalicylic acid (treatment A, B and C)
compared to LPS treatment. Thus, IL-10 reduces significantly at higher concentration compared
to LPS which is the concentration produce with cells induced with LPS. Moreover, TNF-α showed
a significance reduction within the different treatments and concentration compared with LPS.
Thus, TNF-α concentration significantly decrease at 10, 1 and 0.1 mM of acetylsalicylic acid.
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CCL2 proteins secretion showed that using concentration at 10 mM of acetylsalicylic acid and 1
mM using treatment A and B.

The levels of CCL2 secretion decreased compare to LPS (Figure 6). Moreover, for IL-6 presented
significance with all difference concentrations and treatments. Thus, IL-6 and CCL2 did revealed
a reduced protein secreted by inducing cells with acetylsalicylic acid using at 10 and 1 mM, and
also at 10 mM and treatment A at 1 mM the levels of IL-6 were bellowed of the detection limit of
the ELISA kit for IL-6 (pg/mL).
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Figure 6: NR8383 treated induced with acetylsalicylic at three concentrations 0.1, 1 and 10
mM. (A) Concentration of CCL2 in cell induced with LPS and also treated it with ASA
following treatment from Table 1. (B) Concentration of IL-6 in cell induced with LPS and also
treated it with ASA following treatment from Table 1. (C) Concentration of IL-10 in cell
induced with LPS and also treated it with ASA following treatment from Table 1. (D)
Concentration of TNF-α in cell induced with LPS and also treated it with ASA following
treatment from table 1. Data showed significances (*) compared to LPS as determined by
using ANOVA and Tukey post-hoc (p≤0.05) N=3.
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1.2 Gene expression from NR8383 cells treated with acetylsalicylic acid (ASA).

To examine gene expression in the induced cells, LPS was used to induce inflammatory response.
To illustrate, Figure 7 shows each gene expression was compared resting cells (control) with LPS.
Further experiments were measured using as a reference condition (LPS) and compared with each
of the three treatments and each condition. GAPDH was used as a reference gene through all of
the experiments. GADPH is known to play a role in glycolysis and nuclear function inside of the
cell. Other genes that were used for the experiment are listed and described as follows:



Arginase -2 (ARG-2) is known to be down regulated when nitric oxide is up regulated
because ARG-2 and iNOS-2 use a common substrate arginine. Inducing ARG-2 has
showed to down-regulate NO production by depleting arginine (Mori, 2007).



Nitric oxide synthesis type II (iNOS-2) is expressed by the treatment of lipopolysaccharide
(LPS).



Macrophage - associated antigen (CD163) may play an anti-inflammatory role and may be
used as a parameter for monitoring macrophage activation in inflammatory conditions.
Also, CD163 is known to be expressed by cells of the M2c phenotype.



Mannose receptor, C type 1 (CD206) is known to be expressed by the cells of the M2
phenotype.
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Figure 7: NR8383 resting cells (control) compare with LPS. Data showed significances
difference (*). Data showed significances difference (*) compared to LPS using pair wise
fixed reallocation randomization test (N=3). At 50 ng/mL of LPS, iNOS (p=0.05), CD206
(p=0.001), TNF-α (p=0.001) and CCL2 (p=0.001).

Figure 8 shows each gene expression was compared with the reference condition (LPS) and sample
condition (modulator). At 10 and 1 mM of acetylsalicylic acid, data showed up-regulation CD206
and IL-6 in treatment C and IL-10 in treatment B. Thus, gene expressions did show an upregulation for CD206 which is a known marker for the presence of M2. At 1 mM of ASA, data did
not show a significance difference compare to LPS.
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Figure 8: NR8383 treated with acetylsalicylic acid at 10, 1 and 0.1 mM. (A) Cell induced
with LPS and treated with 10 mM of ASA following treatment of Table 1. (B) Cells
induced with LPS and treated with 1 mM of ASA following treatments of Table 1. (C)
Cells induced with LPS and treated with 0.1 mM of ASA following treatments of Table 1.
Data showed significances difference (*) compared to LPS using pair wise fixed
reallocation randomization test. At 10 mM of ASA, treatment B (p=0.02); treatment C
CD206 (p=0.02) and IL-6 (p=0.05); at 0.1 mM of ASA treatment B CD163 (p=0.001) and
IL-6 (p=0.04).
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2.1 Secretion of anti and pro-inflammatory cytokines and gene expression in NR8383 cells
treated with dexamethasone (DEX).

NR8383 rat alveolar cells lines were treated with dexamethasone. The concentration of DEX was
use for this research was previous measure in our lab. At 100 nM, previous studies have showed
to reflect differences in cells induced with LPS, and compare with cells induced with LPS and
treated with DEX. The study used three different treatments at the concentrations displayed in
Table 1. Each of the treatments was incubated for 24 hours.

In Figure 9 showed that with these three different treatments with dexamethasone, it significantly
decreased cytokine protein levels of TNF-α and IL-6. Concentration of IL-6 were below of the
limit of detection, and TNF-α were significantly lower compared to LPS. Moreover, CCL2 did not
show significant change in treatment A and B. However, data showed that the proteins levels of
CCL2 were significantly lower in treatment C. To rephrase treatment C, the cells were stimulated
with LPS and dexamethasone at the same time. Finally, dexamethasone has shown to decrease the
protein secretion of CCL2, IL-6, IL-10 and TNF-α in NR8383 cells lines.
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Figure 9: NR8383 induced with LPS and treated with dexamethasone at 100 nM. (A)
Concentration of CCL2 in cell induced with LPS and also treated it with DEX following
treatment from table 1. (B) Concentration of IL-6 in cell induced with LPS and also treated
it with DEX following treatment from table 1. (C) Concentration of IL-10 in cell induced
with LPS and also treated it with DEX following treatment from table 1. (D) Concentration
of TNF-α in cell induced with LPS and also treated it with DEX following treatment from
table 1. Data showed significances (*) compare with LPS using ANOVA and Tukey as a
post-test (p=0.05) N=3.
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2.2 Gene expression from NR8383 cells treated with dexamethasone (DEX).

NR8383 cells were treated with dexamethasone using 100 nM as shown in Table 1.To summarize,
treatment A involved a first exposure with dexamethasone, and then 80 min later adding LPS. For
treatment B, the cells were induced first with LPS, and then 80 min later treated with
dexamethasone. Finally treatment C, dexamethasone and LPS delivered at the same time.
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Figure 10: NR8383 induced with LPS and then treated with dexamethasone at 100 nM.
treatment A was cells that were induced with dexamethasone and then 80 min later with
LPS, treatment B was cells induced with LPS and then 80 min later with dexamethasone,
and treatment C was cells induced with LPS and dexamethasone at the same time. Data
showed significances compare to LPS using pair wise fixed reallocation randomization test
N=4. At 100 nM, treatment A iNOS (p=0.005), CD163 (p=0.05), CD206 (p≤0.05), TNF-α
(p≤0.02) and CCL2 (p≤0.01), treatment B iNOS (p≤0.01), CD163 (p=0.001), CD206
(p=0.001), CCL2 (p=0.01) and IL-10 (p=0.05) and treatment C iNOS (p≤0.005). CD163
(p≤0.05), CD206 (p=0.05) and CCL2 (p≤0.01).

In Figure 10 treatments A and C exhibited a down-regulation for iNOS and CCL2. iNOS is known
to be up-regulate in cells that are induced with LPS, and CCL2 is known to be a chemokine that
regulates migration and infiltration of cells. Moreover, treatment B showed up-regulation of
CD163, CD206 and IL-10. Thus, dexamethasone up-regulates the anti-inflammatory response by
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up-regulating CD163, CD206 and IL-10 and decreasing pro-inflammatory cytokine response such
as TNF-α and IL-6.

3.1 Secretion of anti and pro-inflammatory cytokines and gene expression in NR8383 cells
treated with prostaglandin E2 (PGE2).

For this experiment, NR8383 cells were treated with prostaglandin E2 (PGE2). The cells were
treated using three different concentrations of PGE2 [1 µM, 100 nM and 10 nM]. PGE2 was used
to treat the cells that were induced of LPS. In Figure 11, data showed significantly difference (IL6 and TNF-α) between cells induce only with LPS, and cells induced and then treated with 1 μM
of PGE2.
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Figure 11: NR8383 induced with LPS and treated with PGE2 following treatment from
Table 1. (A) Concentration of CCL2 (B) Concentration of IL-6 (C) Concentration of IL-10
(D) Concentration of TNF-α. Data showed significance (*) compare to LPS as determined
by using ANOVA and Tukey as a post-test (p=0.05) N=3.
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In Figure 11 the graph shows, the three different concentrations of PGE2 significantly decreased
TNF-α. Also, the concentration of IL-6, known pro-inflammatory cytokine, was measured. The
concentration of IL-6 resulting from treatment with 1 µM of PGE2 was significantly higher
compare with LPS. In addition, Figure 11 revealed that level of CCL2 and IL-10 was not
significantly different compared with LPS. Thus, PGE2 shows a decrease of TNF-α; however, IL10 and CCL2 did not show significant differences.

3.2 Gene expression from NR8383 cells treated with prostaglandin E2 (PGE2).

In the gene expression patterns after PGE2 treatments that are shown in Figure 12. At 1 µM of
PGE2 showed significant gene expression levels of up-regulated ARG2, CD163, and CD206. Also,
at 100 nM of PGE2 showed significant up-regulated gene expression ARG2, CD163, CD206, and
IL-10; however, at 10 nM of PGE2 shown up-regulation ARG2, and CD206. Thus, these three
different concentrations of PGE2 revealed up-regulation for ARG2, and CD206. To recall, ARG2
is known to up-regulate when iNOS is down-regulated, and CD206 is known to be present in cells
that are M2 macrophages. Importantly at 100 nM of PGE2 shows up-regulation of CD163 and IL10 which are known to be anti-inflammatory. Thus, PGE2 is an anti-inflammatory modulator that
decreases significantly the secretion of TNF-α and IL-6, and also up-regulates ARG2, CD206,
CD163 and IL-10 in the gene expression assays.
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Figure 12: NR8383 induced with LPS and treated with PGE2 at three concentration 10 nM,
100 nM and 1 µM. Cells were induced with LPS and treated with prostaglandin E2 at the
same time for each different concentration. Data showed significance difference (*) for
treatments 1 µM [ARG2, CD163 and CD206], 100 nM [ARG2, CD163, CD 206 and IL10], and for 10 nM [ARG2, CD206] using pair wise fixed reallocation randomization test
N=3. At 10 nM ARG2, CD206 and IL-10 [p=0.001], 100 nM ARG2, CD163, CD206 and
IL-10 [p=0.045], and 1 µM ARG2, CD163, CD206 [p=0.001].

4.1 Quality of iloprost.

Recently studies have shown the short half-life of PGI2. The modulator that was used was Iloprost.
Iloprost is the drug analog of PGI2. Because of the short half life time of PGI2, an analysis to
measure the quality of our reagent was performed before using it for cell treatment.
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Figure 13: LC/MS analysis was performing on LCMS-8040 with an ESI ion source
connected to a UPLC. As a solvent was used water and methanol, and each one contained
0.1% of formic acid. Iloprost was run an isocratic run with 65% MeOH/ 35% H2O, 0.6
mL/min as a flow rate and 40°C as a column temperature.

34

Figure 14: Using a selected ion monitoring in the MS, 325.3 [M+ H- 2H2O] +, 343.3 [M+
H- H2O] +, 378.3 [M+ NH4] + and 383.3 [M+ Na] + m/z was followed. These ions are
presented in iloprost, respectively.

In the LC data, it was observed that iloprost is an diastereomers (Schermuly et al., 2002). An
diastereomers are a type of stereoisomer that with two or more stereocenter. These diastereomers
are represented by chromatogaphic peaks that was shown in the standard. In addition to Figure 13,
Figure 14 is the representation of m/z of first peak. As in Figure 14, iloprost is not showing
degradation products. Finally, Figures 13 and 14 shown that iloprost is not degradaing into
unknown molecules, and that our standard could be use as a stock solution in the treatment of
NR8383 cells.
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4.2 Secretion of anti and pro-inflammatory cytokines and gene expression in NR8383 cells
treated with iloprost.

For this experiment, NR8383 cells were treated with iloprost at [1 µM, 100 nM and 10 nM]. In
Figure 15 the graph shows, the three different concentrations.
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Figure 15: NR8383 induced with LPS and treated with iloprost following treatment Table
1. A) Concentration of CCL2 (B) Concentration of IL-6 (C) Concentration of IL-10 (D)
Concentration of TNF-α. Data showed significance (*) compare with LPS determined by
using ANOVA and Tukey as a post-test (p=0.01 (A) and p=0.05(B, C and D)) N=3.

Figure 15 shows a significance decrease of protein cytokine secretion. CCL2, IL-6, IL-10 and
TNF-α show a decrease treated cells with 100 nM and 1 µM of iloprost compared with cells
induced with LPS. Thus, the protein secretion of pro-inflammatory cytokines at 100 nM and 1 µM
of iloprost decrease with in cells that were induced with LPS.
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4.3 Gene expression from NR8383 cells treated with iloprost.

In the gene expression patterns after iloprost treatments that are shown in Figure 16 revealed that
gene expression at 10 nM of iloprost was significantly up-regulated in CD163, CD206 and IL-6.
In cells treated with 100 nM of iloprost showed a significant up-regulate CD206 and IL-6;
however, cells induced with 1 µM showed a significant up-regulation for IL-6. Thus, these three
different concentrations of iloprost revealed an up-regulation of CD163 and CD206. Thus, iloprost
is an anti-inflammatory modulator that decreases significantly the secretion of CCL2 and TNFα,
and also up-regulates CD206, and CD163 in the gene expression.
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Figure 16: NR8383 induced with LPS and treated with iloprost at three concentration 10
nM, 100 nM and 1 µM. Cells were induced with LPS and treated with iloprost at the same
time for each different concentration. Data showed significance difference (*) for
treatments 10 nM [CD163, CD206 and IL-6], 100 nM [CD163, and CD 206], and for 1 µM
[IL-6] using pair wise fixed reallocation randomization test N=3. At 10 nM CD163
(p≤0.02), CD206 (p≤0.05) IL-6 (p=0.001); 100 nM CD206 (p=0.05) IL-6 (p=0.001) and
1µM IL-6 (p=0.05).

5.1 Secretion of anti and pro-inflammatory cytokines and gene expression in NR8383 cells
treated with resolvin D1 (RvD1).

For this experiment, NR8383 cells were treated with RvD1. These cells were treated using three
different concentrations of RvD1 [1 µM, 100 nM and 10 nM]. In Figure 17, the graph shows four
cytokines that were analyzed CCL2, IL-6, IL-10 and TNF-α.
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Figure 17: NR8383 induced with LPS and treated with RvD1 following treatment from
Table 1. A) Concentration of CCL2 (B) Concentration of IL-6 (C) Concentration of IL-10
(D) Concentration of TNF-α. Data showed a significance (*) compare with LPS as
determined by using ANOVA and Tukey as a post-test (p=0.05) N=3.
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Figure 17 showed a significantly decreases [IL-6] in cells induced with LPS and then treated with
10 nM of RvD1. Thus, RvD1 does not significantly decrease the secretion of pro-inflammatory
cytokines such as TNF-α, and CCL2. Moreover, RvD1 also does not significantly increase antiinflammatory cytokines such as IL-10. However, RvD1 significantly decrease the concentration of
IL-6 at 10 nM of treatment.

5.2 Gene expression from NR8383 cells treated with resolvin D1 (RvD1).

In the gene expression patterns after RvD1 treatments that are shown in Figure 18 revealed that
only cells treated with 100 nM of RvD1 were significantly up-regulated in IL-10. Thus, at 10 nM
and 1 µM concentrations of RvD1 does not revealed neither an up-regulation nor down-regulation
of ARG2, iNOS, CD206, CD163, IL6 and IL-10.
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Figure 18: NR8383 induced with LPS and treated with resolvin D1 at three concentration
10 nM, 100 nM and 1 µM. Cells were induced with LPS and treated with RvD1 at the same
time for each different concentration. Data showed significance difference (*) for
treatments 10 nM [IL-10] using pair wise fixed reallocation randomization test (p=0.001)
N=3.
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DISCUSSION

Our study presents five different modulators that are known to shift the microenvironment from
pro-inflammation, which can be induced with LPS, to a wound healing. The five modulators, that
our study measured, were acetylsalicylic acid (ASA), dexamethasone (DEX), prostaglandin E2
(PGE2), iloprost and resolvin D1 (RvD1). Moreover, the cytokines responses and macrophage
activation of the NR8383 cell was measured by inducing the cell with LPS and then treating them
with each one of these modulators. Then, our study concludes with the importance in the selection
of a modulator that can be used as a powerful guidance for in vivo modulator studies.

1. NR8383 cells treated with Acetylsalicylic acid (ASA).

Macrophages are known to secrete pro-inflammatory cytokines and regulate the activation of proinflammatory gene which can be regulated by the activation of NF-κB. The activation of NF-κB
leads to the secretion of inflammatory cytokines: TNF-α, IL-1, IL-6, IL-8, IFN-β and other
cytokines (Kopp and Ghosh, 1994). ASA had demonstrated to be an anti-inflammatory agent due
to the partial inhibition (approximate 75%) of the endogenous IKK kinase activity (Yin et al.,
1998). Moreover, aspirin, also known as an acetylsalicylic acid, significantly can inhibit cells that
were induced with LPS, and also suppressed mRNA accumulation and secretion of TNF-α at 0.1
mM concentration (Shackelford et al., 1997).

Our data showed a spike of IL-10, TNF-α, CCL2 and IL-6 inducing with LPS at 24 hours of
incubation; however cells treated with ASA, our data showed a significant decrease of cytokines
levels. Similar response were observed by the knock-down macrophage migration inhibitors
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factors (MIF) in murine ovarian cancer cells (Hagemann et al., 2007). Moreover at 10 mM of ASA,
our data revealed a decrease of TNF-α, CCL-2 and IL-6 which are known to be pro-inflammatory.
In addition to the cytokine levels, cells treated at 1 mM of ASA, our data did not show different
regulation. However for cells treated at 10 mM of ASA (qRT-PCR data), our data showed upregulation of IL-10 in treatment B (LPS, and then 80 minutes later the modulator), and also CD206,
and IL-6 for treatment C (LPS and the modulator at the same time). Moreover for 0.1 mM, our
data showed an up-regulation of CD163 in treatment B. Thus, the protein secretion shows a
decrease of pro-inflammatory cytokines in the protein secretion; however, IL-10 which is an antiinflammatory cytokines shows a significant decrease in cells treated with ASA. Also, the gene
expression show an up-regulation IL-10, CD206 and CD163 which are known to be up-regulation
in anti-inflammatory microenvironment or wound healing response.

2. NR8383 cells treated with dexamethasone (DEX).

Dexamethasone is also known to be an anti-inflammatory glucocorticoid due to inhibition of NFκB and activator protein-1 (AP-1) pathway. In addition, NF-κB and AP-1 inhibition,
dexamethasone is known to reduce pro-inflammatory cytokine: TNF-α, IL-8, and IL-6. Similar to
others studies, our data showed a decrease of IL-6, TNF-α, and IL-10. To illustrate, the antiinflammatory response of the dexamethasone, it can be display by the lowering of cytokine levels
that are known to be pro-inflammatory. However, our data also showed a decrease of IL-10 which
is a known to be an anti-inflammatory cytokine. In addition, dexamethasone did not significantly
affect CCL2 in treatments A and B. However, cells, that were treated with dexamethasone and at
the same time induced with LPS (treatment C), our data shown a significant decrease of CCL2
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levels. To recall, CCL2 is a chemokines that is known to recruit of cells in to the site of
inflammation.

Gene expression of DEX at 100 nM, for treatments A and C showed similar regulation. In
treatments A and C, iNOS and CCL2 were down-regulated. To illustrate, iNOS and CCL2 downregulation shows the inhibition effect of DEX. On the other hand, treatment B has shown a
different regulation compare to treatments A and C. To recall, treatment B (LPS, and then 80
minutes later the modulator) were cells that were induced with LPS, and then 80 min later were
treated with DEX. Cells treated using treatment B shows an up-regulation of CD163, CD206 and
IL-10. Thus, treatment B illustrated the presence of M2 macrophage which were not showed in
treatment A and C. Also, in treatment B has shown an up-regulation CD163 which is a scavenger
receptor which is known to be expressed by cells of the M2c phenotype, and also an up-regulation
of IL-10 which is a known cytokine which is known to drive macrophage to the M2 phenotype.
Even though, IL-10 show a decrease in the protein levels, in the gene expression showed the upregulation of these anti-inflammatory cytokine. Finally, dexamethasone has showed a decrease of
pro-inflammatory cytokines and an up-regulation of M2 phenotype; on the other hand, one side of
effect of dexamethasone has shown to slowdown: wound healing at 1 mg/kg in patients, ulcer
healing in rats, and muscle proteins in healthy patients (Luo et al., 2004; Minetto et al., 2010;
Schermuly et al., 2002).
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3. NR8383 cells treated with prostaglandin E2 (PGE2).

Prostaglandin E2 is a known lipid mediator that is derived from arachidonic acid (AA). Moreover,
PGE2 is also known to be an anti-inflammatory lipid mediator. In the process of reestablishment
homeostasis, PGE2 and prostaglandin D2 triggers a changing from the generation of leukotriene B4
to the production of lipoxin A2. A shift from inflammation into homeostasis is mediated by a switch
of an increase of the secretion of pro-resolution lipid mediators such as E and D-series of resolvin
and protectins (Serhan et al., 2008). Our data showed that PGE2 at 10, 100 nM and 1 µM decreased
the concentration of TNF-α. Moreover, the decrease concentration of TNF-α can be represented
by homeostasis response of PGE2. PGE2, also, has showed to increase IL-6 in cells treated at 1µM.
However, IL-6 is a known signaling molecule that is secreted as a pro-inflammatory response, but
also IL-6 can be expressed as an inhibitory effect of TNF-α and IL-1 (Ataie-Kachoie et al., 2014).
Our data did show a significant increase of IL-6. This is consistent with recent studies showed by
R. M. Hinson, J. A. Willians and E. Shacter, PGE2 can cause an increase in IL-6 proteins levels.
The expression of COX-2 may mediate the higher expression of IL-6 in murine model (Hinson et
al., 1996). However, our data did not shown a significantly change in the secretion of IL-10 and
CCL2.

For PGE2, our data shows an up-regulation of ARG2, and CD206 genes at 10 nM. For 100 nM,
our data shows an up-regulation of ARG2, CD163, CD206 and IL-10 genes, and for 1 µM, an upregulation of ARG2, CD163 and CD206 genes. Our data shows the expression of M2 phenotype
in our treated cells; however, only at 1 µM and 100 nM is expressed the wound heling macrophage
which is the represented by the marker CD163 (M2c phenotype). In addition, at 100 nM is
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expressed the up-regulation of IL-10. Finally, PGE2 has showed the anti-inflammatory effect by
decreasing TNF-α protein secretion, and also by the up-regulation of CD163, CD206 and IL-10.

4. NR8383 cells treated with iloprost.

Recently studies have shown that the half-life of PGI2 is approximate 14.5 min at 4 °C in aqueous
solution (Cho and Allen, 1978). The analog of PGI2 that was used in our experiment was iloprost.
Iloprost is a drug that has been used in the treatment of pulmonary arterial hypertension (PAH),
scleroderma, and others types of diseases. Moreover, iloprost is known to be a potent antiinflammatory drug (Al-Shorbagy et al., 2012). Our data shown, the cells treated with iloprost the
concentration of TNF-α, IL-6, CCL2 and IL-10 decrease compare to the cells that were only induce
with LPS. The anti-inflammatory response of iloprost is presented by the decrease of proinflammatory cytokine such as CCL2, IL-6 and TNF-α. Finally, iloprost is a drug that is
represented as an analog of PGI2. Iloprost showed to be a potent anti-inflammatory drug in cells
induced and then treated with it.

For the gene expression of iloprost showed an up-regulation at 10 nM of CD163, CD206 and IL6. At 100 nM showed an up-regulation of CD206 and IL-6 and in cells treated with 1 µM showed
an up-regulation of IL-6. At lowered concentration is possible to observe the presence of M2 and
M2c phenotype which is known to be a characteristic of anti-inflammatory microenvironment.
Thus, iloprost presented an anti-inflammatory drug because of the decrease of cytokines such as
TNF-α, CCL2, and IL-6 and also showed the up-regulation of gene such as CD206, CD163 and
IL-6.
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5. NR8383 cells treated with Resolvin D1 (RvD1).

Recently studies have shown that administrated a high dose (from milligrams to grams) of omega3 can be beneficial to many inflammatory disease (Serhan et al., 2008). Resolvins are derived for
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) the two from E-series and D-series,
respectively. Resolvin D1 has shown in other studies to stops the recruitment of neutrophil and
protect against neovascularization in mouse (Serhan et al., 2008). Moreover, DHA can derived to
group referred to as 17S and 17 R D- series, and also both has shown to block the production of
TNF-α in the treatment of neural injury (Serhan et al., 2008). Our study shows that cells treated
with RvD1 did not shown a significantly change the concentration of cytokines such as CCL2, IL10 and TNF-α. However, IL-6 showed a significantly decrease at 10 nM of RvD1.

In the gene expression for 10 nM and 1 µM, our data did not show a significantly change compare
to LPS. On the other hand, cells that were treated with RvD1 at 100 nM showed an up-regulation
of IL-10. Thus, RvD1 has shown to be an anti-inflammatory modulator because of the upregulation of IL-10 in the gene expression.
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CONCLUSION

Our data has showed that ASA, DEX, iloprost, and PGE2 are an anti-inflammatory modulator in
macrophage (NR8383 cells).

Each modulator has presented to be able to decrease the

concentration of pro-inflammatory cytokines response; however, not all of them have shown to
increase anti-inflammatory cytokines levels. Each modulator has shown to act differently to reach
homeostasis. For that reason each modulator can be used depending on the solution that is looking.
To illustrate, RvD1 is known to come from a family that can be administrated high dose in the
treatment of inflammation. On the other hand, DEX has showed that is limited by their long
therapeutic because of the inhibition of AP-1 pathway (Vayssiere et al., 1997). AP-1 is a
transcription factor which is known to control the difference cellular process such as
differentiation, proliferation and transformation (Angel and Karin, 1991). Moreover, ASA is an
anti-inflammatory modulator; however, high dose is needed it to obtain the anti-inflammatory
response. Iloprost and PGE2 are lipid mediator that are derived for omega-6, and our study shown
has shown the anti-inflammatory response of these two modulators. In addition, iloprost and PGE2
can be presented as an anti-inflammatory modulator, but more work is needed it. Thus, all five
modulator has shown that can be used to decrease the pro-inflammatory response. Depending on
the work that it is needed, it is possible preference the modulator that can effectively be used
depending off each situation. Future work, further analysis will be necessary to determine any
functional of these modulator in in vivo starting with PGE2. For this reason is needed the analysis
of using one of each modulator using peritoneal macrophage and/or spleen macrophage.
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Table 3: Summary of data

Modulator

Concentration

0.1 mM

Acetylsalicylic
acid (ASA)

1 mM

10 mM

100 nM (A)

Dexamethasone
(DEX)

100 nM (B)

100 nM (C)

Upregulation
gene
expression

Downregulation
gene
expression

Increase
protein
secretion

Decrease
protein
secretion

N/A

IL-6,
IL-10 (C)
TNF-α

CD163
IL-10 (C)

N/A

N/A

CCL2,
IL-6,
IL-10(A),
IL-10(C),
TNF-α

N/A

N/A

N/A

CCL2,
IL-6,
IL-10,
TNF-α

IL-10 (B)
CD206 (C)

N/A

N/A

IL-6,
IL-10,
TNF-α

N/A

iNOS
CCL2

N/A

IL-6,
IL-10,
TNF-α

CD-163,
CD-206
IL-10

N/A

N/A

CCL2,
IL-6,
IL-10,
TNF-α

N/A

iNOS
CCL2
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10 nM

Prostaglandin
E2 (PGE2)

Iloprost

Resolvin D1
(RvD1)

100 nM

N/A

TNF-α

N/A

TNF-α

1 μM

IL-6

TNF-α

10 nM

N/A

CCL2,
IL-6,
TNF-α

N/A

CCL2,
IL-6,
IL-10
TNF-α

1 μM

ARG2,
CD-206

ARG2,
CD163,
CD206
IL-10

ARG2,
CD163,
CD206

N/A

N/A

N/A

CD206,
IL-6

N/A

CD206
IL-6

N/A

N/A

CCL2,
IL-6,
IL-10
TNF-α

IL-6

N/A

10 nM

N/A

IL-6

N/A

N/A

100 nM

N/A

N/A

IL-6

N/A

1 μM

N/A

N/A

N/A

N/A

100 nM

Table 3: Data of NR8383, cells were induced with LPS and treated with a modulator.
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